Dianthus Therapeutics

Dianthus is a private biotechnology company focused on the discovery and development of monoclonal antibody therapies that modulate the immune auxiliary system for the treatment of autoimmune diseases. The company is developing a new generation of complement therapy, DNTH103, which is a novel monoclonal antibody that selectively targets the activated form of the complement C1s protein.